The U.S. Food and Drug Administration (FDA) today approved a weekly subcutaneous starting dose for Leqembi, marking the first time patients can begin Alzheimer's treatment with at-home administration, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results